It's the pharmacokinetically correct route for any protocol where dermal remodeling is the endpoint
Beyond insulin resistance in NASH: TNF-alpha or adiponectin
In my experience, BPC-157 is especially useful for acute and subacute injuries where the goal is to reduce pain, calm local tissue irritation, support healing, and help the patient tolerate rehabilitation and progressive loading more effectively
Early studies on Gly-His-Lys (GHK), first discovered in human plasma in the 1970s, demonstrated their ability to modulate gene expression, stimulate collagen synthesis, and accelerate wound healing, sparking broad interest in these bioactive molecules [23]
If you use sterile water, its stability drops to only a few days
Compare GHK-Cu (Copper Peptide) by mechanism, evidence strength, expected timeline, side-effect profile, and whether its primary use case matches your goal